Radius Health Osake

Radius Health EBITDA

Delisted·10.7.2025

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Radius Health (RDUS) 12.8.2026 päivämäärällä on −294,54 M USD. Edellisenä vuonna EBITDA (Tulos ennen korkoja, veroja ja poistoja) oli −3,93 M USD — muutos 7 404,08 % (matalampi).

EBITDA

−294,54 MUSD

YoY

7 404,08%

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Radius Health on 2026 −294,54 M USD. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Radius Health oli 2025 −3,93 M USD. Se laskee 7 404,08% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Radius Health Osakeanalyysi

Mitä Radius Health tekee? Radius Health Inc. is an American pharmaceutical company specializing in the research, development, and marketing of products in the areas of osteoporosis, cancer therapy, and endocrinology. The company was founded in 2003 and is headquartered in Waltham, Massachusetts. The history of Radius Health Inc. began with the discovery of a new compound called Abaloparatide, which was intended for use in the treatment of osteoporosis. The company initiated a Phase III clinical trial to evaluate the efficacy and tolerability of the medication. In 2016, Abaloparatide was approved by the U.S. Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis. Since then, Radius Health Inc. has evolved into a leading company specializing in improving women's health. The company has expanded its activities to include oncology and endocrinology and relies on innovative technologies and research to provide better treatment options and medications for patients. The business model of Radius Health Inc. is based on the development and marketing of cost-effective and effective products for the treatment of diseases. The company conducts extensive clinical research and strives to develop new drugs and therapies to improve the lives of women. Radius Health Inc. employs an open and agile corporate culture that promotes innovation and prioritizes the needs of patients. The products offered by Radius Health Inc. include a wide range of medications used in the treatment of osteoporosis, breast cancer, and other diseases. Abaloparatide, the company's flagship product, is a recombinant peptide agonist that stimulates bone formation and reduces the risk of fractures in postmenopausal women. Other products include Elacestrant, an investigative drug for the treatment of breast cancer, and RAD1901, a selective estrogen receptor modulator used in the treatment of hormone-dependent cancers. The company is also active in the field of digital health. Radius Health Inc. has developed an augmented reality app that assists doctors and patients in visualizing bone fractures and other conditions. The app is currently being tested in clinical trials and is expected to be widely used in the future. Overall, Radius Health Inc. is known for its innovative research activities and efforts to improve women's health. The company has an experienced and dedicated team of researchers, scientists, and executives working together to create better treatment options for patients. With a strong pipeline of products and a vision for the future of healthcare, Radius Health Inc. is on track to become a leading provider of medical products and services. Radius Health on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Radius Health osakkeesta

Yhtiön Radius Health EBITDA (Tulos ennen korkoja, veroja ja poistoja) on −294,54 M USD vuonna 2026.

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Radius Health muuttui arvosta −3,93 M USD arvoon −294,54 M USD, mikä edustaa 7 404,08 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBITDA (Tulos ennen korkoja, veroja ja poistoja) Radius Health:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA mittaa operatiivista suorituskykyä ennen rahoitusrakenteen, veroympäristön ja muiden kuin käteispoisto-osuuksien vaikutusta.

EBITDA = EBIT + Poistot

EBITDA (Tulos ennen korkoja, veroja ja poistoja):n USD on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata EBITDA (Tulos ennen korkoja, veroja ja poistoja):n Radius Health historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Tuloslaskelma — Radius Health

Kaikki tunnusluvut — Radius Health